APA (7th ed.) Citation

Wang, X., Li, Z., Wang, L., Liang, Y., Huang, C., Chen, P., . . . Jiang, R. (2025). Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: Results from a multicenter phase II study with ctDNA analysis. BMC Medicine, 23(1), 1. https://doi.org/10.1186/s12916-025-04044-8

Chicago Style (17th ed.) Citation

Wang, Xinyue, et al. "Osimertinib Plus Anlotinib for Advanced NSCLC with Acquired EGFR T790M Mutation: Results from a Multicenter Phase II Study with CtDNA Analysis." BMC Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12916-025-04044-8.

MLA (9th ed.) Citation

Wang, Xinyue, et al. "Osimertinib Plus Anlotinib for Advanced NSCLC with Acquired EGFR T790M Mutation: Results from a Multicenter Phase II Study with CtDNA Analysis." BMC Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12916-025-04044-8.